Drug Approval | December 29, 2021
U.S. FDA approves Leo Pharma’s Adbry
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
Zeebon is the largest diagnostics services provider in North-Eastern states
The product is expected to be available in a week’s time
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
This product will be manufactured at Lupin's Goa facility in India
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
Subscribe To Our Newsletter & Stay Updated
